We investigated relationships between cytomegalovirus (CMV) seropairing and CMV
prophylaxis on graft outcome in recipients of solid organ transplants. Transplants carried out …

Background. We studied the economic impact of cytomegalovirus (CMV) disease and its
effective reduction with antiviral prophylaxis in liver transplant recipients. Method. Analysis of …

Background Antiviral prophylaxis is commonly used in recipients of solid-organ transplants
with the aim of preventing the clinical syndrome associated with cytomegalovirus infection …

Cytomegalovirus (CMV) infection is an important complication of solid-organ transplantation.
The availability of potent antiviral therapies has decreased the incidence of CMV disease …

Objective We compared the effectiveness of lower‐dose (LD)(450 mg/day for 6 months) to
standard‐dose (SD)(900 mg/day for 6 months) valganciclovir (VGCV) prophylaxis for …

Background Although initial therapy for cytomegalovirus (CMV) is usually successful, a
significant subset of patients may have recurrent viremia. However, the epidemiology and …

The risk of late-onset cytomegalovirus (CMV) infection remains a concern in seronegative
kidney and/or pancreas transplant recipients of seropositive organs despite the use of …

Objective: To assess the efficacy of high-dose oral acyclovir therapy compared with
preemptive, short-course ganciclovir therapy (administered only if cytomegalovirus [CMV] …

Background The risk of cytomegalovirus (CMV) infection in solid organ transplant recipients
has resulted in the frequent use of prophylaxis with the aim of preventing the clinical …

Cytomegalovirus (CMV) is a cause of considerable morbidity and mortality among orthotopic
liver transplant (OLT) recipients. To study the impact of CMV on cost and hospital length of …